REPONEX PHARMACEUTICALS A/S: Financial statements 2019
CVR: 30082346
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
REPONEX PHARMACEUTICALS A/S (CVR 30082346) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 0 and a net result of DKK -1,853,921 compared with DKK -1,256,682 the year before. Equity in the 2019 report amounted to DKK 14,933,340. The solvency ratio was 85.3%.
- Revenue
- DKK 0
- Gross Profit
- DKK 0
- Profit/Loss
- DKK -1,853,921
- Equity
- DKK 14,933,340
- Total Assets
- DKK 17,501,729
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | 0 | 0 | -1.9 mio. | 14.9 mio. | - |
| 2018 | 0 | 0 | -1.3 mio. | 2.4 mio. | - |
| 2017 | - | -1.3 mio. | -1.6 mio. | 3.7 mio. | - |
| 2016 | - | 242 t. | -332 t. | 5.2 mio. | - |
| 2015 | - | -1.2 mio. | -934 t. | 536 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
REPONEX PHARMACEUTICALS A/S has published its annual report for 2018. Revenue came to DKK 0, and the net result was DKK -1,256,682.
As of June 17, 2019, Troels Peter Troelsen has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of June 17, 2019, Sigbjørn Georg Nielsen Kjærgård has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
As of June 17, 2019, Henrik Bulskov has left the board of directors of REPONEX PHARMACEUTICALS A/S.
As of June 16, 2019, Troels Peter Troelsen has left the board of directors of REPONEX PHARMACEUTICALS A/S.
About REPONEX PHARMACEUTICALS A/S
REPONEX PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named REPONEX PHARMACEUTICALS ApS and TRIFOILIUM ApS. The management consists of Christian Henrik Tange. The board consists of Christian Vinding Thomsen (chair), Troels Peter Troelsen and Charlotte Pahl. The company is owned by Pharma Equity Group A/S. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -6,570,000 compared with DKK -11,943,000 the year before. Equity in the 2025 report amounted to DKK 4,645,000.